The ribbon-cutting ceremony for the new building of Proteintech's German R&D center. [Photo/WeChat account of Optics Valley of China]

Recently, the new building of the German R&D center of Proteintech, a company based in East Lake High-tech Development Zone (also known as Optics Valley of China, or OVC), was officially put into use. Located in Martinsried, Germany, the building will be engaged in the development of the human blood protein nanobody array program and other research and development work.

In 2020, Proteintech Group acquired the German company Chromotek, which specializes in the development and production of innovative nanobody reagents. With the relocation to the new building, the company will provide a larger platform and channels for the development and sales of its products.

Li Jianxun, CEO of Proteintech. [Photo/WeChat account of Optics Valley of China]

Li Jianxun, CEO of Proteintech, stated that nanobody technology has tremendous prospects, and the company is pleased to be at the forefront of this field. Proteintech has research and production laboratories in Chicago, Wuhan, and Martinsried, all of which have expanded over the past three years. In the future, the synergy between these bases can help the company introduce more innovative products to the global market.